Company intelligence / Profile preview

Oravax Medical

Ownership: Private
Development stage: Phase 3

Overview

Oravax’s oral COVID‑19 vaccine candidate has shown positive preliminary Phase 1 data. The VLP triple antigen approach targets three structural proteins of SARS-CoV‑2, aiming for broad protection against variants. The oral format offers advantages in distribution and administration, especially in regions with limited healthcare infrastructure. Clinical trials have begun in South Africa and are planned or underway in other regions including Israel.

Therapeutic areas: Infectious Diseases
Modalities: Oral virus-like particle (VLP) vaccines
Industry: Biotech

Drug pipeline

1 asset

ORMD-0801

Phase 3

Indications: Type 2 diabetes, NASH

Partnerships

Genomma Lab Internacional S.A.B. de C.V.: Joint venture for development/commercialization in Mexico/Latin AmericaPremas Biotech Pvt Ltd.: Technology partner/co-founder

Beyond the preview

Go deeper on Oravax Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oravax Medical.

Explore the full profile